✦ LIBER ✦

Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid

✍ Scribed by Masanobu Tsuda; Yuki Moritoki; Zhe-Xiong Lian; Weici Zhang; Katsunori Yoshida; Kanji Wakabayashi; Guo-Xiang Yang; Toshio Nakatani; John Vierling; Keith Lindor; M. Eric Gershwin; Christopher L. Bowlus

Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 904 KB
Volume: 55
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.24748

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Atorvastatin in patients with primary bi

Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid

✍ Tatjana Stojakovic; Csilla Putz-Bankuti; Günter Fauler; Hubert Scharnagl; Martin 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 207 KB 👁 1 views

Statin therapy may target both hypercholesterolemia and cholestasis in primary biliary cirrhosis (PBC). However, little is known about the efficacy and safety of statins in PBC. The aim of this single-center study was therefore to prospectively examine the effects of atorvastatin on serum markers of

Biochemical response to ursodeoxycholic

Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis

✍ Christophe Corpechot; Ludovico Abenavoli; Nabila Rabahi; Yves Chrétien; Tony And 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 186 KB 👁 1 views

Biochemical response to ursodeoxycholic acid (UDCA) in patients with primary biliary cirrhosis (PBC) is variable. It has been recently proposed that an alkaline phosphatase (ALP) decline of more than 40% in baseline value or a normal level after 1 year of UDCA treatment (Barcelona criteria) could se

Comment on biochemical response to ursod

Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis

✍ Lucy J. Walker; Julia Newton; David E. J. Jones; Margaret F. Bassendine 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

We read with interest the article by Corpechot et al. in a recent issue of HEPATOLOGY. 1 Corpechot et al. identify the absence of a biochemical response to ursodeoxycholic acid (UDCA) as an important predictive factor for death or liver transplantation in patients with primary biliary cirrhosis (PBC

Cholesterol-lowering effect of ursodeoxy

Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis

✍ Renée E. Poupon; Khadija Ouguerram; Yves Chrétien; Claudine Verneau; Eveline Esc 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 591 KB

We have previously shown in a 2-yr controlled trial that hypercholesterolemia, frequent in primary biliary cirrhosis, is lowered by ursodeoxycholic acid (13 to 15 mg daily). To further investigate this effect, we analyzed the influence of long-term ursodeoxycholic acid administration on serum lipids

Oral budesonide in the treatment of pati

Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid

✍ Paul Angulo; Roberta A. Jorgensen; Jill C. Keach; E. Rolland Dickson; Coleman Sm 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 236 KB 👁 1 views

Ursodeoxycholic acid (UDCA) is a safe and effective medical therapy for most patients with primary biliary cirrhosis (PBC). However, some patients show an incomplete response to UDCA therapy. Treatment with corticosteroids may be of benefit although at the expense of systemic side effects. Budesonid

Ursodeoxycholic acid–induced changes of

Ursodeoxycholic acid–induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis

✍ Adolf Stiehl; Gerda Rudolph; Richard Raedsch; Bernd Moller; Ulrich Hopf; Erich L 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 596 KB

Ursodeoxycholic acid treatment of patients with primary biliary cirrhosis may lead to relief of pruritus and improvement of biochemical liver tests. The changes in serum and urinary bile acids induced by ursodeoxycholic acid treatment were studied. After 29 patients with primary biliary cirrhosis we